Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy

The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes is steadily increasing. SGLT2 inhibitors are associated with weight loss, lowering of blood pressure, and low hypoglycemia risk along with beneficial cardiovascular and renoprotective effects. In view o...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadokostaki, Eleni, Liberopoulos, Evangelos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526544/
https://www.ncbi.nlm.nih.gov/pubmed/31198610
http://dx.doi.org/10.1155/2019/3901741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526544/
https://www.ncbi.nlm.nih.gov/pubmed/31198610
http://dx.doi.org/10.1155/2019/3901741

Ejemplares similares